Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.

scientific article published on March 2006

Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/ARD.2005.044248
P932PMC publication ID1798050
P698PubMed publication ID16474039
P5875ResearchGate publication ID7302728

P50authorCheuk Chun SzetoQ37840506
Lai-Shan TamQ70947037
P2093author name stringC W K Lam
W-C Li
E K Li
C-K Wong
P2860cites workUpdating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosusQ29614922
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Q44441787
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectlupus nephritisQ1621830
P304page(s)417-418
P577publication date2006-03-01
P1433published inAnnals of the Rheumatic DiseasesQ4767876
P1476titleSafety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial
P478volume65

Reverse relations

cites work (P2860)
Q338824904SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice
Q37960525Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus
Q33882751Current status of lupus nephritis
Q91934535Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Q28304479Effective treatment of Kimura's disease with leflunomide in combination with glucocorticoids
Q36634248Emerging drug therapies for systemic lupus erythematosus
Q53192338Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats.
Q24193098Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome
Q92874652Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus
Q36302245Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Q45969377Leflunomide-induced polymyositis in a patient with rheumatoid arthritis.
Q28274721Leflunomide: friend or foe for systemic lupus erythematosus?
Q51608298Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy.
Q34498515Systemic lupus erythematosus: review of synthetic drugs
Q38285375The multifaceted aspects of refractory lupus nephritis
Q42728756Treatment of lupus nephritis
Q37690745Update on emerging drug therapies for systemic lupus erythematosus

Search more.